Dianthus Therapeutics, Inc. /DE/ Diluted Shares Outstanding (Weighted Average)
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Diluted Shares Outstanding (Weighted Average) of 56.03 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 56.03M shares, a 56.41% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 48.03M shares, a 34.20% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 45.04M shares, a 27.20% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 37.79M shares, a 10.39% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for fiscal 2025 was 38.62M shares, a 15.92% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for fiscal 2024 was 33.31M shares, a 546.44% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for fiscal 2023 was 5.15M shares, a 489.48% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ weighted average number of shares outstanding, diluted for fiscal 2022 was 874.23K shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 56.03M shares 10-Q · filed 2026-08-04 | 52.05M shares 10-Q · filed 2026-08-04 | 49.70M shares derived: average of 3 quarters · filed 2026-08-04 | 46.72M shares derived: average of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | 48.03M shares 10-Q · filed 2026-05-05 | 46.54M shares derived: average of 2 quarters · filed 2026-05-05 | 43.62M shares derived: average of 3 quarters · filed 2026-05-05 | 41.67M shares derived: average of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | 45.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 41.42M shares derived: average of 2 quarters · filed 2026-03-09 | 39.55M shares derived: average of 3 quarters · filed 2026-08-04 | 38.62M shares 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | 37.79M shares 10-Q · filed 2025-11-05 | 36.81M shares derived: average of 2 quarters · filed 2026-08-04 | 36.48M shares 10-Q · filed 2025-11-05 | 36.20M shares derived: average of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | 35.82M shares 10-Q · filed 2026-08-04 | 35.81M shares 10-Q · filed 2026-08-04 | 35.67M shares derived: average of 3 quarters · filed 2026-08-04 | 35.32M shares derived: average of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | 35.79M shares 10-Q · filed 2026-05-05 | 35.60M shares derived: average of 2 quarters · filed 2026-05-05 | 35.15M shares derived: average of 3 quarters · filed 2026-05-05 | 34.92M shares derived: average of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | 35.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 34.82M shares derived: average of 2 quarters · filed 2026-03-09 | 34.62M shares derived: average of 3 quarters · filed 2026-03-09 | 33.31M shares 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | 34.24M shares 10-Q · filed 2025-11-05 | 34.23M shares derived: average of 2 quarters · filed 2025-11-05 | 32.61M shares 10-Q · filed 2025-11-05 | 27.26M shares derived: average of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | 34.23M shares 10-Q · filed 2025-08-07 | 31.79M shares 10-Q · filed 2025-08-07 | 24.94M shares derived: average of 3 quarters · filed 2025-08-07 | 19.68M shares derived: average of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | 25.67M shares 10-Q · filed 2025-05-12 | 20.29M shares derived: average of 2 quarters · filed 2025-05-12 | 14.83M shares derived: average of 3 quarters · filed 2025-05-12 | 11.34M shares derived: average of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | 14.92M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 9.42M shares derived: average of 2 quarters · filed 2025-03-11 | 6.57M shares derived: average of 3 quarters · filed 2025-03-11 | 5.15M shares 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | 3.91M shares 10-Q · filed 2024-11-07 | 2.39M shares derived: average of 2 quarters · filed 2024-11-07 | 1.90M shares 10-Q · filed 2024-11-07 | 1.63M shares derived: average of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | 874.90K shares 10-Q · filed 2024-08-08 | 60.65M shares 10-Q · filed 2023-08-03 | 874.80K shares 10-Q · filed 2024-08-08 | 60.65M shares 10-Q · filed 2023-08-03 | 874.71K shares derived: average of 3 quarters · filed 2024-08-08 | 874.61K shares derived: average of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | 874.71K shares 10-Q · filed 2024-05-09 | 60.65M shares 10-Q · filed 2023-05-15 | 874.62K shares derived: average of 2 quarters · filed 2024-05-09 | 874.52K shares derived: average of 3 quarters · filed 2024-05-09 | 15.36M shares derived: average of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | 874.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 874.42K shares derived: average of 2 quarters · filed 2024-03-21 | 20.19M shares derived: average of 3 quarters · filed 2024-03-21 | 874.23K shares 10-K · filed 2024-03-21 | 59.37M shares 10-K · filed 2023-03-23 | |||
| 2022-09-30 | 874.33K shares 10-Q · filed 2023-11-09 | 59.27M shares 10-Q · filed 2022-11-03 | 29.84M shares derived: average of 2 quarters · filed 2023-11-09 | 874.14K shares 10-Q · filed 2023-11-09 | 58.96M shares 10-Q · filed 2022-11-03 | -9.75M shares derived: average of 4 quarters · filed 2023-12-21 | ||
| 2022-06-30 | 58.82M shares 10-Q · filed 2023-08-03 | 58.81M shares 10-Q · filed 2023-08-03 | -13.29M shares derived: average of 3 quarters · filed 2023-12-21 | 4.68M shares derived: average of 4 quarters · filed 2023-12-21 | ||||
| 2022-03-31 | 58.80M shares 10-Q · filed 2023-05-15 | -49.34M shares derived: average of 2 quarters · filed 2023-12-21 | -13.36M shares derived: average of 3 quarters · filed 2023-12-21 | 3.40M shares derived: average of 4 quarters · filed 2023-12-21 | ||||
| 2021-12-31 | -157.47M shares derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | -49.44M shares derived: average of 2 quarters · filed 2023-12-21 | -15.06M shares derived: average of 3 quarters · filed 2023-12-21 | 873.47K shares 8-K · filed 2023-12-21 | 54.95M shares 10-K · filed 2022-03-08 | |||
| 2021-09-30 | 58.58M shares 10-Q · filed 2022-11-03 | 56.14M shares derived: average of 2 quarters · filed 2022-11-03 | 53.66M shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 53.71M shares 10-Q · filed 2022-08-04 | 51.15M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 48.57M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 43.92M shares 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |